BioSingapore, the premier life sciences association serving the biotech, medtech and biopharma community in Singapore, recently launched the inaugural “BioSingapore Innovative Biomedical Company Award” that aims to recognize companies that are in the cutting edge of innovation in the Singapore biosciences sector.
The winner of this year’s inaugural BioSingapore Innovative Biomedical Company Award was ASLAN Pharmaceuticals. The CEO of ASLAN Pharmaceuticals, Dr Carl Firth received the award from the Chairman of BioSingapore, Dr Ong Siew Hwa.
ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, to treat Asia prevalent tumour types. Currently, they are developing five drugs that address multiple indications including biliary tract cancer, gastric cancer and breast cancer, as well as one modybodies platform. Their lead drug ASLAN001 or Varlitinib has been awarded the Orphan Drug Designation in cholangiocarcinoma and gastric cancer by the United States FDA, as well as the Korea Ministry of Food and Drug Safety for biliary tract cancer.
The first runner-up was MirXes Pte Ltd which has developed a proprietary ultra-sensitive quantitative technology to detect blood-borne microRNA cancer biomarkers. They are currently running the world’s largest prospective clinical studies for early stage gastric, lung and breast cancer diagnostics utilizing the miRNA biomarkers they have discovered.
ClearBridge Biomedics’s ClearCell® Systems andCTChip® helps to detect wholly intact Circulating Tumour Cells (CTCs) from patients’ blood samples for early cancer diagnosis. They are on the path to revolutionize cancer management with the ability to detect cancer easily with a simple blood draw, termed as liquid biopsy as opposed to the conventional invasive solid tissue biopsy.
Synphne Pte Ltd, a spin-off from NTU, is a wearable, connected brain-rewiring solution which helps to restore brain and limb function in people suffering from various forms of brain-muscle disability arising from stroke, cerebral palsy, traumatic brain injury, childhood development delay and aging. Synphne has been conducting R&D including product development for the past 8 years and plans to launch its first global product in 2017 for restoring independence in using the upper limb. Their technology will undergo a clinical trial at Harvard Medical School.
Dr Subhasis, co-founder of Synphne remarked, “It is wonderful to be recognized with an award at a Pharma Conference when we are a medical technology company. It shows that the industry is moving towards a convergence, at least in mind space, between drugs based and non-drugs based approaches to important global human health challenges, of which chronic disability is the biggest.”
The winning companies were awarded for spearheading innovations and for having demonstrated efficient and sustainable business practices in business while expanding their market access.
The awards were announced at the recently concluded BioPharma Asia Convention 2017, organized by Terrapin Pte Ltd.